Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Pascal, Deschatelets"'
Publikováno v:
Exploration of Immunology, Vol 4, Iss 5, Pp 577-615 (2024)
Complement is both evolutionary and scientifically old. It predates the adaptive immunity by some 600 million years and was first described in 1905 by Jules Bordet and Paul Ehrlich. For the most of its, the existence complement system has been ignore
Externí odkaz:
https://doaj.org/article/d960d2e9f48249b4adb31d88b480549f
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 17, p 9477 (2024)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening hematologic disorder caused by a somatic mutation in a relevant portion of hematopoietic stem cells. Mutation of the phosphatidylinositol glycan biosynthesis class A
Externí odkaz:
https://doaj.org/article/5cc94dede1a54d24803c5aab152ac612
Autor:
Corinne J. Smith, Nikki Ross, Ali Kamal, Kevin Y. Kim, Elizabeth Kropf, Pascal Deschatelets, Cedric Francois, William J. Quinn, Inderpal Singh, Anna Majowicz, Federico Mingozzi, Klaudia Kuranda
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
AAV gene transfer is a promising treatment for many patients with life-threatening genetic diseases. However, host immune response to the vector poses a significant challenge for the durability and safety of AAV-mediated gene therapy. Here, we charac
Externí odkaz:
https://doaj.org/article/d9b0d374702f4585b36b080c36e4089e
Autor:
Martin Kolev, Madhumita Das, Monica Gerber, Scott Baver, Pascal Deschatelets, Maciej M. Markiewski
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The role of complement in cancer has received increasing attention over the last decade. Recent studies provide compelling evidence that complement accelerates cancer progression. Despite the pivotal role of complement in fighting microbes, complemen
Externí odkaz:
https://doaj.org/article/1d9f607e85c3424b9f5a277c18a5dae6
Autor:
Raymond Siu Ming Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia, Yeow Tee Goh, Henry Idrobo, Daolada Kongkabpan, David Gómez-Almaguer, Mohammed Al-Adhami, Temitayo Ajayi, Paulo Alvarenga, Jessica Savage, Pascal Deschatelets, Cedric Francois, Federico Grossi, Teresita Dumagay
Publikováno v:
Blood Advances. 7:2468-2478
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aef03eed0e45d20bd5d3611131ef8d5
https://doi.org/10.1182/bloodadvances.2022009129
https://doi.org/10.1182/bloodadvances.2022009129
Autor:
Régis Peffault de Latour, Jeff Szer, Ilene C Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean-Jacques Kiladjian, Carlos M de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, Federico Grossi, Antonio M Risitano, Peter Hillmen
Publikováno v:
The Lancet Haematology. 9:e648-e659
Background: In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60ab63e2045057bfd66a5ed680184665
https://doi.org/10.1016/s2352-3026(22)00210-1
https://doi.org/10.1016/s2352-3026(22)00210-1
Autor:
Raymond S M, Wong, Humphrey W H, Pullon, Ismail, Amine, Andrija, Bogdanovic, Pascal, Deschatelets, Cedric G, Francois, Kalina, Ignatova, Surapol, Issaragrisil, Pimjai, Niparuck, Tontanai, Numbenjapon, Eloy, Roman, Jameela, Sathar, Raymond, Xu, Mohammed, Al-Adhami, Lisa, Tan, Eric, Tse, Federico V, Grossi
Publikováno v:
Annals of Hematology. 101:1971-1986
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemoly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3bf846b1cc5dce676c8a819f23bd2e2
https://doi.org/10.1007/s00277-022-04903-x
https://doi.org/10.1007/s00277-022-04903-x
Publikováno v:
Immunological reviewsREFERENCES.
C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell-derived, and intracellular C3 plays critical roles in the immune response that is dysregulated in many diseases, making it an attr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd45801166687c34f4ad60e6db98b23a
https://pubmed.ncbi.nlm.nih.gov/36161656
https://pubmed.ncbi.nlm.nih.gov/36161656
Autor:
David S. Boyer, Cedric G. Francois, Felix Grassmann, Delphine El Mehdi, Bernhard H. F. Weber, Philip J. Rosenfeld, Ramiro Ribeiro, Jason S. Slakter, Robert Y. Kim, Carol Chung, David Liao, Jeffrey S. Heier, Prema Abraham, David M. Brown, Charles C. Wykoff, Federico Grossi, Monica Gerber, Mohamed Hamdani, Lawrence J. Singerman, Pascal Deschatelets, Peter Nuernberg
Publikováno v:
Ophthalmology. 127:186-195
Objective Geographic atrophy (GA), a late stage of age-related macular degeneration, is a major cause of irreversible blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable compromise of visual fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::641ac4b6cc099d8a06241f34a6589cae
https://doi.org/10.1016/j.ophtha.2019.07.011
https://doi.org/10.1016/j.ophtha.2019.07.011
Autor:
Pascal Deschatelets, Carlos M. de Castro, Hisakazu Nishimori, Britta Höchsmann, Morag Griffin, Antonio M. Risitano, Ilene C. Weitz, Kensuke Usuki, Alexander Röth, Régis Peffault de La Tour, Mohamed Hamdani, Temitayo Ajayi, Peter Hillmen, Cedric G. Francois, Lisa Tan, Jens Panse, Federico Grossi, Jean-Jacques Kiladjian, Jeff Szer
Publikováno v:
The New England journal of medicine. 384(11)
Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df883fd386d00ff51c01fab70727eb9
https://pubmed.ncbi.nlm.nih.gov/34706184
https://pubmed.ncbi.nlm.nih.gov/34706184